236687 Type 2 Diabetes as a Food-Borne Illness

Sunday, October 30, 2011

Claudia Delman, MPH, CHES , Physicians Committee for Responsible Medicine, Washington, DC
The modern epidemic of type 2 diabetes in the United States needs to be re-evaluated by examining the role of the “Standard American Diet” (SAD) in the leading causes of mortality and morbidity. The spate of chronic diseases like diabetes, heart disease, and certain cancers are clear outcomes of the SAD. Lacking the acute onset and rapid progression of symptoms seen in food-borne illnesses caused by pathogens like H1N1, salmonella, E. coli, or typhoid, chronic disease (CD) may not be recognized as a food-borne illness, but certain CDs survive within this construct, and are definable and thus preventable and treatable in many of the same ways. This presentation makes the argument that the current epidemic of type 2 diabetes needs to be labeled as a “food-borne illness,” and that appropriate interventions are in the domains of nutrition and public health. As such, public health policy interventions for the prevention and treatment of type 2 diabetes must focus on food availability, promotion, and consumption.

Learning Areas:
Administer health education strategies, interventions and programs
Advocacy for health and health education
Chronic disease management and prevention
Public health or related research

Learning Objectives:
1. Define “food-borne illness” 2. Evaluate key literature on the impact of the Western diet on prevalence of type 2 diabetes. 3. Compare key literature on the impact of vegetarian nutrition to manage type 2 diabetes. 4. Describe an effective public health response to diabetes as a food-borne illnesses.

Keywords: Diabetes, Prevention

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have a Master in Public Health and this is my area of expertise.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.